[Hematology 2008].
Klinik I für Innere Medizin, Universitätsklinikum, Joseph-Stelzmann Str. 9, 50924 Köln. elisabeth.albrecht@uk-koeln.de
P
P
Borchmann
B
B
Eichhorst
M
M
Hellmann
K
K
Hübel
M
M
Kochanek
Karl-Anton
KA
Kreuzer
K
K
Kreuzer
M
M
Reiser
M
M
Hallek
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D003131:Combined Modality Therapy; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D006402:Hematologic Diseases / Q000175:diagnosis / Q000628:therapy*; D019337:Hematologic Neoplasms / Q000175:diagnosis / Q000628:therapy*; D006457:Hemoglobinuria, Paroxysmal / Q000175:diagnosis / Q000628:therapy; D006801:Humans; D009025:Morpholines / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D000069552:Rivaroxaban; D013876:Thiophenes / Q000627:therapeutic use; D013923:Thromboembolism / Q000628:therapy
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D005343:Fibrinolytic Agents; D009025:Morpholines; D013876:Thiophenes; D000069552:Rivaroxaban; C481642:eculizumab